Known Pharmacokinetic Interactions
Azacitidine and ruxolitinib can interact through cytochrome P450 enzymes. Ruxolitinib is metabolized primarily by CYP3A4, and azacitidine may indirectly influence CYP activity via its effects on DNA methylation, potentially altering ruxolitinib clearance. No severe pharmacokinetic interactions are widely documented, but monitoring is advised in combination therapy, common in myelofibrosis or MDS treatment.[1]
Clinical Use and Observed Effects
The combination is used off-label or in trials for conditions like myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Studies report no major adverse interactions, but increased myelosuppression (e.g., thrombocytopenia, neutropenia) occurs due to overlapping toxicities rather than direct drug-drug effects. Dose adjustments for ruxolitinib may be needed if azacitidine causes cytopenias.[2][3]
What Happens in Patients on Both
Patients report higher infection risk and fatigue from additive bone marrow suppression. No contraindications exist, but guidelines recommend CBC monitoring weekly during co-administration. Ruxolitinib's JAK inhibition does not directly affect azacitidine's hypomethylating action.[4]
Alternatives if Interactions Concern You
Switch to venetoclax + azacitidine (less CYP overlap) or fedratinib (JAK inhibitor with different metabolism) for similar indications. Pacritinib avoids CYP3A4 reliance.[1][5]
Guidance from Prescribers
Consult Lexicomp or Micromedex for patient-specific checks; no black-box warnings for this pair. In trials like those for post-MPN AML, the combo shows feasibility without emergent interactions.[3]
Sources
[1]: Drugs.com Interaction Checker
[2]: UpToDate: Ruxolitinib in Myelofibrosis
[3]: NCT03844048 ClinicalTrials.gov (Azacitidine + Ruxolitinib)
[4]: Medscape Drug Interaction Tool
[5]: FDA Ruxolitinib Label